Novatek Pharmaceuticals

Early Stage

Development of immunomodulatory drugs



Dealmaker Securities

Start Date


Close Date


Min. Goal


Max. Goal


Min. Investment


Security Type

Equity - Common


Series A

Funding Type


Price Per Share


Pre-Money Valuation



Pearland, Texas


Healthcare & Pharmaceuticals

Tech Sector


Distribution Model




Capital Intensity


Business Type


Novatek Pharmaceuticals, with a valuation of $5 million, is raising funds on Dealmaker Securities. It is a pharmaceutical company focused on the development of immunomodulatory drugs related to cancers and infectious diseases. The aim of Novatek Pharmaceuticals’ investigations is to develop drugs to empower naturally-derived immunotherapy and reduce the adverse effects of disease and cytotoxic therapies. Novatek Pharmaceuticals is led by an experienced team and has several products in clinical trials. Mohamed Kaseb founded Novatek Pharmaceuticals in April 2020. The current crowdfunding campaign has a minimum target of $50,000 and a maximum target of $5 million. The campaign proceeds will be used for marketing, research and development, manufacturing, and general working capital.

Summary Profit and Loss Statement

Most Recent Year Prior Year












Net Income



Summary Balance Sheet

Most Recent Year Prior Year




Accounts Receivable



Total Assets



Short-Term Debt



Long-Term Debt



Total Liabilities



Financials as of: 01/04/2023
Create a free account today to gain access to KingsCrowd analytics.

Upgrade to gain access

Pay Monthly
Annually (Save 17%)


$12.42 /month
billed annually
Free portfolio tracking and KingsCrowd's quantitative ratings on all raises.
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings (excluding risk)
Advanced company search ( with ratings)
Markets page filters and historical industry data
Get Edge Annual

Edge Pro

$41.58 /month
billed annually
Full site access including KingsCrowd's qualitative analyst reports.
Plan Includes:
Everything in Edge, plus
Full access to detailed Analyst Reports (e.g. Top Deal, Deal to Watch, Neutral, and Underweight)
Search and filter based on Analyst Reports
In-depth risk ratings for every raise
Get Edge Pro Annual
Already a member? Log in here.

Ratings KingsCrowd Startup Rating Methodology Article

Create your first portfolio

Create your very own investment portfolio on KingsCrowd.

Now you can track all of your startup investments in one place utilizing our state-of-the-art portfolio tracker tools. To begin, create your first portfolio below.

Add to portfolio
Novatek Pharmaceuticals on Dealmaker Securities 2023
Platform: Dealmaker Securities
Security Type: Equity - Common
Valuation: $5,000,000

Follow company

Follow Novatek Pharmaceuticals on Dealmaker Securities 2023
View on Dealmaker Securities